7 completed, 2 withdrawn, 1 recruiting. 10 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 7, Withdrawn 2, Recruiting 1 |
| Phase 3 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Conjunctivitis, Bacterial: new trials by email Literature Review of Conjunctivitis, Bacterial trials Research Report on Conjunctivitis, Bacterial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis SUM-191, Placebo - Bacterial Conjunctivitis | Phase 1 / Phase 2 | Recruiting | Senju USA, Inc. | 426 | 2026-06-25 | 2026-06-30 |
| Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults RD03/2016 eye drops, Levofloxacin 0.5% eye drops solution (Oftaquix®) - Conjunctivitis, Bacterial | Phase 2 | Completed | NTC srl | 252 | 2021-11-05 | 2024-09-27 |
| Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma IR3535, Permethrin lower dose, Permethrin higher dose - Trachoma | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 64 | 2019-01-10 | 2020-04-08 |
| Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) PRO-157, Vigamox, Zymar® - Bacterial Conjunctivitis | Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 150 | 2015-03-01 | 2019-05-22 |
| Nepal Elimination of Trachoma Study Azithromycin - Trachoma | Phase 2 / Phase 3 | Withdrawn | University of California, San Francisco | 2014-08-01 | 2015-05-21 | |
| Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis Auriclosene Solution 0.3%, Auriclosene Vehicle - Bacterial Conjunctivitis | Phase 2 | Completed | NovaBay Pharmaceuticals, Inc. | 217 | 2013-06-01 | 2015-05-28 |
| Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension, AL-15469A 0.5%, AL-6515 0.3% - Bacterial Conjunctivitis | Phase 2 | Withdrawn | Alcon Research | 2011-01-01 | 2011-12-01 | |
| Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Besifloxacin, Vehicle (Placebo) - Bacterial Conjunctivitis | Phase 2 / Phase 3 | Completed | Bausch & Lomb Incorporated | 474 | 2009-10-01 | 2012-03-29 |
| Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis ISV-403, Vehicle - Bacterial Conjunctivitis | Phase 2 | Completed | Bausch & Lomb Incorporated | 270 | 2004-12-01 | 2015-03-24 |
| Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis 0.5% levofloxacin eye drops - Bacterial Conjunctivitis | Phase 2 / Phase 3 | Completed | Laser Microsurgery Centre, Poland | 119 | 2004-09-01 | 2007-11-29 |
Trachoma (2) · Conjunctivitis (1)
Bacterial Infections (10) · Bacterial Infections and Mycoses (10) · Conjunctival Diseases (10) · Eye Diseases (10) · Eye Infections (10) · Eye Infections, Bacterial (10) · Infections (10) · Conjunctivitis (9) · Chlamydia Infections (2) · Chlamydiaceae Infections (2) · Corneal Diseases (2) · Gram-Negative Bacterial Infections (2)
Ophthalmic Solutions (2) · besifloxacin (2) · Azithromycin (1) · Gatifloxacin (1) · Levofloxacin (1) · Moxifloxacin (1) · NVC-422 (1) · Permethrin (1) · ethyl-3-(N-n-butyl-N-acetyl)aminopropionate (1) · pazufloxacin (1)
Bausch & Lomb Incorporated (2) · Alcon Research (1) · Laboratorios Sophia S.A de C.V. (1) · Laser Microsurgery Centre, Poland (1) · London School of Hygiene and Tropical Medicine (1) · NTC srl (1) · NovaBay Pharmaceuticals, Inc. (1) · Senju USA, Inc. (1) · University of California, San Francisco (1)
United States (3) · Ethiopia (1) · Germany (1) · Italy (1) · Mexico (1) · Nepal (1) · Poland (1) · Russia (1) · Spain (1) · United Kingdom (1)
Bruce D Gaynor, MD (1) · David W. Stroman, Ph.D. (1) · Francesco Bandello, Prof. (1) · Jerzy Szaflik, MD,Ph.D. (1) · Leopoldo Baiza, MD (1) · Michael R Paterno, OD (1) · Timothy Comstock, OD (1)
PMID 19393842, PMID 20629472, PMID 21397770, PMID 22420526, PMID 22644963, PMID 29602567, PMID 32841261, PMID 35747196
K23EY019881 (1)